Joyita Dutta, PhD
Co-Founder
Generative AI for Radiopharmaceutical Therapy (RPT)
The radiopharmaceutical therapy (RPT) field has accelerated rapidly following the recent FDA approvals of drugs like Pluvicto for prostate cancer and Lutathera for neuroendocrine tumors. Building on our research on AI models for computing radiopharmaceutical dose from pre- and post-therapy imaging data, we proposed to create VIRTUOSO or Virtual Individualized Radiotheranostics Trial Utility for Outcome Simulation and Optimization, a software platform for RPT dosimetry and outcome prediction.
